Innopharma, Inc. was acquired by Pfizer, Inc on September 25, 2014. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_innopharma -------------------------------------------------------------------------------------------------------------------------------------------------------- InnoPharma, Inc. develops niche generic and specialty pharmaceutical/bio-pharmaceutical products in sterile dosage forms, and out-licenses to pharmaceutical marketing companies for commercialization. The “Niche Generics” program is targeted on developing those generic drug products that are: •Difficult to develop for technical reasons, especially injectable and ophthalmic dosage forms •None or very limited API source •Niche area of use •Complicated manufacturing •Complicated bio-equivalency or clinical studies •Potential to provide value to patients and prescribers, in terms of cost effectiveness Visit us at: http://innopharmainc.com